As of May 18
| +0.04 / +1.47%|
The 1 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +8.30% increase from the last price of 2.77.
The current consensus among 1 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.